* With an aging population, there's a rising demand.
Go here to see the original:
Health Net Federal Services, Penn State and Red Cross Host Chicago Symposium to Better Equip Local Health Care …
RANCHO CORDOVA, Calif.--(BUSINESS WIRE)--
Health Net Federal Services, LLC, a wholly-owned subsidiary of Health Net, Inc. (HNT), today announced its continued partnership with PennState Milton S. Hershey Medical Center and Penn State College of Medicine and the American Red Cross, through its Service to the Armed Forces program, to promote the last in a series of four symposiums entitled, Meeting the Needs of Returning Military Service Members, for primary care physicians and behavioral health professionals in the Chicago-area and part of the TRICARE North Region.
As this years series of behavioral health symposiums comes to a close in Chicago, we are very proud to know that the hundreds of physicians and behavioral health professionals who have attended these symposiums are better equipped to assess and treat the invisible wounds of war, said ThomasCarrato, president, Health Net Federal Services. The enthusiasm and interest from those who attended the symposiums speaks to the collective commitment within our region to the resiliency and well-being of our service members and their families who sacrifice so much for our country.
Topics that are scheduled to be discussed at the symposium include post-traumatic stress disorder (PTSD) assessment tools and list factors that impact screening among military personnel; emerging technologies that support psychological health and brain injury recovery in the military community; mechanisms of injury and Department of Defense diagnostic criteria for mild, moderate, severe and penetrating traumatic brain injury (TBI); clinical practice guidelines for the management of mild TBI in non-deployed settings; contrasting the components of a differential diagnosis of TBI and/or PTSD; and understanding challenges faced by returning service members and program benefits available to them.
The symposium will be conducted by leaders from the Center for Deployment Psychology at the Uniformed Services University, the National Center for Telehealth and Technology, and the Defense and Veterans Brain Injury Center. Penn State College of Medicine is accredited by the Accreditation Council of Continuing Medical Education to provide continuing medical education for physicians, APA and NASW credits for behavioral health professionals, and credits for nurses also are available. This symposium has been designated for 7.0 continuing medical education (CME) hours.
The full-day symposium is expected to be held Dec. 8, 2012, at the Adler School of Professional Psychology, 17 North Dearborn Street, Community Room, in Chicago, Ill. Interested physicians and behavioral health care professionals can register by fax or by mail. Agenda, credits and registration details can be found at http://www.pennstatehershey.org/ce.
The TRICARE North Region includes Connecticut, Delaware, Illinois, Indiana, Kentucky (except Fort Campbell), Maine, Maryland, Massachusetts, Michigan, New Hampshire, New Jersey, New York, North Carolina, Ohio, Pennsylvania, Rhode Island, Vermont, Virginia, West Virginia, Wisconsin and the District of Columbia. In addition, the TRICARE North Region covers a small portion of Missouri and Iowa.
About Health Net
Health Net, Inc. is a publicly traded managed care organization that delivers managed health care services through health plans and government-sponsored managed care plans. Its mission is to help people be healthy, secure and comfortable. Health Net, through its subsidiaries, provides and administers health benefits to approximately 5.4million individuals across the country through group, individual, Medicare (including the Medicare prescription drug benefit commonly referred to as Part D), Medicaid, U.S.Department of Defense, including TRICARE, and Veterans Affairs programs. Health Nets behavioral health services subsidiary, Managed Health Network, Inc., provides behavioral health, substance abuse and employee assistance programs to approximately 4.9million individuals, including Health Nets own health plan members. Health Nets subsidiaries also offer managed health care products related to prescription drugs, and offer managed health care product coordination for multi-region employers and administrative services for medical groups and self-funded benefits programs.
For more information on Health Net, Inc., please visit Health Nets website at http://www.healthnet.com.
See original here:
Health care law talks meet cries of 'tyranny'
By Travis Pillow Florida Capital Bureau -- Florida lawmakers face a series of key decisions on the federal health care law, and on Monday they got their first taste of how contentious those decisions will be.
Originally posted here:
Martin’s Point Health Care Selects athenahealth to Achieve Operational Productivity
WATERTOWN, Mass. & PORTLAND, Maine--(BUSINESS WIRE)--
athenahealth, Inc. (ATHN), a leading provider of cloud-based electronic health record (EHR), practice management, and care coordination services to medical groups and health systems, today announced that Martins Point Health Care, a medical group and health plan administrator with nearly 90 providers, will implement athenahealths integrated suite of services to optimize productivity and improve care delivery across its clinical network.
Martins Point will implement athenahealths Best in KLAS EHR service, streamlined medical billing and practice management service, and patient communication services across all of its health care centers. Additionally, Martin's Point Health Care will be utilizing health care business intelligence services from Anodyne Health Partners, Inc., an athenahealth company.
We are very excited to partner with athenahealth, said David Howes, MD and President and CEO of Martins Point Health Care. Their cloud-based services will help us work more efficiently, allowing us to focus on delivering the highest quality care and the best patient experience while lowering costs.
We at athenahealth are thrilled to be chosen by Martins Point Health Care, said Jonathan Bush, Chairman and CEO, athenahealth. As an insurance payer and a provider group with nearly 90 providers, they are in the unique position to truly change the way primary care is delivered in Maine. We are particularly pleased and honored to welcome our largest client in this state, where we have offices and employ more than 500 people.
About athenahealth
athenahealth, Inc. is a leading provider of cloud-based Best in KLAS electronic health record (EHR), practice management, and care coordination services to medical groups and health systems. athenahealths mission is to be the most trusted service to medical care givers, helping them do well by doing the right thing. For more information, please visit http://www.athenahealth.com or call 888-652-8200.
About Martins Point Health Care
Martins Point is a progressive, not-for-profit, health care organization, with experience and demonstrated excellence in both clinical patient care and health plan administration. Martins Point has nine health care centers in Maine and New Hampshire as well as three health care plans for select groups throughout the northeast. Martins Point is committed to improving the experience of care, improving health outcomes and reducing the overall cost of care. To achieve these goals, Martins Point is working to make systemic changes to the way primary care is delivered and coordinated. For more information, please visit http://www.MartinsPoint.org.
Continue reading here:
Martin’s Point Health Care Selects athenahealth to Achieve Operational Productivity
Inflammation may be a cause of plaque buildup in heart vessels
Fifteen new genetic regions associated with coronary artery disease have been identified by a large, international consortium of scientists -- taking a significant step forward in understanding the root causes of this deadly disease.
Go here to read the rest:
Inflammation may be a cause of plaque buildup in heart vessels
International study points to inflammation as a cause of plaque buildup in heart vessels
( Stanford University Medical Center ) Fifteen new genetic regions associated with coronary artery disease have been identified by a large, international consortium of scientists -- including researchers at the Stanford University School of Medicine -- taking a significant step forward in understanding the root causes of this deadly disease.
See more here:
International study points to inflammation as a cause of plaque buildup in heart vessels
Genetic variation recent, varies among populations
Nearly three-quarters of mutations in genes that code for proteins -- the workhorses of the cell -- occurred within the past 5,000 to 10,000 years, fairly recently in evolutionary terms, said a national consortium of genomic and genetic experts, including those at Baylor College of Medicine.
Go here to read the rest:
New Book on Genome and Personalized Medicine Preps Doctors for Changing Reality
An all-new edition of Genomic and Personalized Medicine promises to be a one-stop shop for doctors and other health professionals as they face the rapid growth of genetic and genomic testing in the clinic.
Original post:
New Book on Genome and Personalized Medicine Preps Doctors for Changing Reality
Personalized Molecular Medicine Firm Genection Launched
NEW YORK (GenomeWeb News) – A personalized molecular medicine company offering physicians access to clinically actionable genetic tests has been launched.
Follow this link:
Partners going personal
CAMBRIDGE -- With personalized medicine becoming a key focus for medical research and diagnosing conditions, Partners HealthCare System, the region’s largest hospital and physicians network, is positioning itself to become a national leader in the emerging field.
Here is the original post:
The Truth About Genetic Engineering – Video
The Truth About Genetic Engineering
This is the truth about genetic engineering, Genetic modification, and genetic enhancement.From:seaweed603Views:0 0ratingsTime:11:47More inNews Politics
See the article here:
Far Cry 3 Live Action Trailer (VAAS STORY) – Video
Far Cry 3 Live Action Trailer (VAAS STORY)
Far Cry 3 is an open world first-person shooter set on a tropical island unlike any other. This is a place where heavily armed warlords traffic in slaves. Where outsiders are hunted for ransom. And as you embark on desperate quest to rescue your friends, you realize that the only way to escape this darkness... is to embrace it. Far Cry 3 releases December 4th on Xbox 360, PlayStation 3, and PC. For more information go to http://www.farcrygame.com. -- Story of the franchise: Far Cry is a first-person shooter video game developed by Crytek Studios and published by Ubisoft on March 23, 2004, for Microsoft Windows. Far Cry sold 730000 units within four months of release.[1] It received positive reviews upon release. The original game has since spawned a series of sequels and spin-off games and a movie. The game #39;s story follows a former US Army Special Forces operative Jack Carver, who is stranded on a mysterious archipelago. He is searching for a female journalist he was escorting after she went missing when their boat was destroyed by mercenaries. The game includes thematic elements relating to the dangers of weaponizing genetic engineering and the genocide of local islanders as can be seen by the deformed creatures created by a mad scientist named Krieger. The terrain in Far Cry varies greatly. Set on a South Pacific archipelago, the landscape includes beaches, dense rain forests, towering canyons, mines, swamps, and even volcanic forests. Many of the interiors range from simple ...From:Michael MyersViews:0 1ratingsTime:02:40More inFilm Animation
Read more:
Reading history through genetics
A Columbia Engineering study published in the November 2012 issue of The American Journal of Human Genetics demonstrates a new approach used to analyze genetic data to learn more about the history of populations. The authors, the first to develop a method that can describe in detail events in recent history, focused on two populations, the Ashkenazi Jews and the Masai people of Kenya.
More here:
Bread Wheat's Genetic Code Breakthrough
Scientists from the United States, United Kingdom and Germany recently completed the first analysis of the bread wheat genome, one of the "big three" global crops upon which mankind depends for nutrition.
Read the original post:
Genetic breakthrough could guarantee wheat supplies
A group of international scientists has cracked the complex genetic code of wheat, offering the prospect of global food security in one of the world's most important crops.
Read the original:
Are there racial disparities in osteoporosis screening and treatment?
( Mary Ann Liebert, Inc./Genetic Engineering News ) Racial differences in the rates of detection and management of osteoporosis were explored in a study of African American and white women published in Journal of Women's Health.
More here:
Are there racial disparities in osteoporosis screening and treatment?
Genes and Inheritance [12]: Gene Therapy (A Level Biology) – Video
Genes and Inheritance [12]: Gene Therapy (A Level Biology)
Thanks for watching. Please subscribe and take a look at our full list of tutorials for other revision videos: http://www.freeeschool.blogspot.co.ukFrom:Free E SchoolViews:0 0ratingsTime:07:40More inEducation
Read more:
Genes and Inheritance [12]: Gene Therapy (A Level Biology) - Video
VGTI Florida Announces New Director of Business Development
PORT ST. LUCIE, Fla.--(BUSINESS WIRE)--
The Vaccine and Gene Therapy Institute of Florida (VGTI Florida) is pleased to announce the appointment of Catherine E. Vorwald to Director, Business Development.
We dedicate ourselves every single day to finding novel treatments for chronic diseases like cancer and HIV/AIDS, said Mel Rothberg, Chief Operating Officer, VGTI Florida. Were pleased to have Catherine onboard. By leading our business development efforts, she will facilitate the commercial translation of therapeutic discoveries so that patients around the world will ultimately be better served and suffer less, he continued.
Catherine will work closely with VGTI Florida leadership to develop and implement a comprehensive strategic approach including growing the intellectual property portfolio, commercializing therapeutic discoveries, and developing an innovation center, based on the institutes technology, for new entities and emerging companies wishing to co-locate and utilize the core facilities and expertise available at the Tradition Center for Innovation.
VGTI Florida has a wealth of expertise and therapeutic discovery potential and I am dedicated to translating these capabilities to industry so that they become a standard part of medical care, said Catherine.
As an accomplished technology commercialization executive, Catherine brings extensive domestic and international biotechnology and life science management experience to VGTI Florida. She specializes in fostering relationships between the academic and corporate communities. Catherine spent nearly six years as Director of Business Development working on marketing and leasing activities for Wexford Science + Technology, LLC, a real estate developer of university technology research parks. Her career encompasses technology commercialization from a variety of aspects, namely, marketing and business development at companies ranging from Fortune 500 to start-ups, academic research at the National Institutes of Health (NIH) and the University of California, San Francisco and technology transfer at Stanford and Johns Hopkins Universities.
Catherine has served as a board member of two notable technology incubators, the Emerging Technology Center of Baltimore and the Economic Development Corporation of South Florida. She is a former board member of The Licensing Executives Society USA-Canada, Inc., and the LES Foundation. She also founded the Licensing Executives Society Maryland Local Chapter. Catherine holds a Master of Business Administration in Finance from The Johns Hopkins University as well as a Master of Science Degree from Georgetown University and a Bachelor of Arts in Biological Sciences from the University of California.
VGTI Florida
VGTI Florida is a leading immunological research institute that is on an urgent mission to transform scientific discoveries into novel treatments and cures for devastating chronic illnesses such as cancer and HIV/AIDS. VGTI Florida is an independent non-profit 501 (c) 3 organization located in the Tradition Center for Innovation in Port St. Lucie, Florida. For more information, please visit our website at http://www.VGTIfl.org.
Go here to see the original:
uniQure Licenses RNA Interference Technology to Advance Huntington's Disease Program
AMSTERDAM, The Netherlands, December 5, 2012 /PRNewswire/ --
uniQure B.V., a leader in the field of human gene therapy, today announced a non-exclusive cross-licensing agreement with Benitec Biopharma Ltd. (BLT.AX) giving uniQure access to Benitec's proprietary DNA-directed RNA interference (ddRNAi) technology in Huntington's disease. In return, uniQure granted Benitec non-exclusive access to the Company's AAV5 delivery technology for the development of a ddRNAi therapy for Hepatitis B.
"The cross-licensing agreement with Benitec fully capitalizes on the strength of our advanced AAV platform and our proven ability to deliver therapeutic genes to target cells with high accuracy and efficacy," says Jrn Aldag, CEO of uniQure. "The agreement with Benitec opens up promising new avenues to develop therapies for high unmet medical needs such as Huntington's disease. While our current programs focus on delivering fully functioning therapeutic genes to remedy faulty or malfunctioning genes, Benitec's ddRNAi technology will allow us to do the opposite - to 'silence' the gene responsible for producing the mutant protein that lies at the basis of Huntington's disease, and to develop a therapy for this devastating disease."
Dr Peter French, CEO of Benitec Biopharma, commented, "Benitec Biopharma is very pleased to have executed this licensing agreement with uniQure, the first company to achieve market approval for a gene therapy product, Glybera, in the West. uniQure have demonstrated their unique ability to take gene therapy-based programs from pre-clinical stages to commercialization, and we are confident that they will be able to achieve a similar outcome in this program. Importantly this agreement also provides Benitec access to uniQure's AAV delivery technology enabling further development of our ddRNAi treatment for Hepatitis B."
About Huntington's disease
Huntington's disease (HD) is a rare, chronic, incurable, progressive and disabling neurological condition, which continues to challenge the medical community. About 30,000 Americans (or 1 in 10,000 people) have Huntington's disease and at least 150,000 individuals have a 50% chance of inheriting the disease. The symptoms of HD become most evident in adulthood, typically 30 to 55 years, characterized by sudden, abnormal, and uncontrolled jerky movements called chorea. Currently, therapeutics for HD are limited only to symptomatic treatments and there are no treatment options with proven safety and efficacy to slow down disease progression or enhance survival rate.
About uniQure
uniQure is a world leader in the development ofhuman gene based therapies.uniQure's Glybera, a gene therapy for the treatment of lipoprotein lipase deficiency has been approved in the European Union, and is the first approved gene therapy in the Western world. uniQure's product pipeline of gene therapy products in development comprise hemophilia B, acute intermittent porphyria, Parkinson's disease and SanfilippoB. Using adeno-associated viral (AAV) derived vectors as the delivery vehicle of choice for therapeutic genes, the company has been able to design and validate probably the world's first stable and scalable AAV manufacturing platform.This proprietary platform can be applied to a large number of rare(orphan) diseases caused by one faulty gene, and allows uniQure to pursue its strategy of focusing on this sector of the industry. uniQure's largest shareholders are Forbion Capital Partners and Gilde Healthcare, two of the leading life sciences venture capital firms in the Netherlands. Further information can be found at http://www.uniqure.com.
About Benitec Biopharma
Benitec Biopharma Ltd is developing novel treatments for chronic and life-threatening conditions based on targeted gene-silencing activity using a transformational technology: DNA-directed RNA interference (ddRNAi) - sometimes called expressed RNAi. The technology's potential to address unmet medical needs and to cure disease results from its demonstrated ability to permanently silence genes which cause the condition. Importantly, this technology's target gene and related gene pathways will rarely have presented as a therapeutic avenue for research for the traditional small molecule agents, currently accounting for the majority of today's pharmaceutical products.
Read the original here:
uniQure Licenses RNA Interference Technology to Advance Huntington's Disease Program
Futurist in Residence at the Ringling College of Art + Design – Video
Futurist in Residence at the Ringling College of Art + Design
Why a futurist in residence at a four year college?From:David HouleViews:0 0ratingsTime:01:17More inTravel Events
See original here:
Futurist in Residence at the Ringling College of Art + Design - Video